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Currently, vitiligo lacks a validated Physician Global Assessment (PGA) for disease 
extent. This PGA can be used to stratify and interpret the numeric scores obtained 
by the Vitiligo Extent Score (VES). We investigated the interrater reliability of a 5‐
point PGA scale during an international vitiligo workshop. Vitiligo experts from five 
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Defining disease severity is a useful means to stratify patients and 
to guide treatment decisions in disease management. In dermatol‐
ogy, three well‐known tools to define disease severity are found in 
the fields of psoriasis and eczema. The Psoriasis Area and Severity 
Index (PASI) is a scoring instrument to measure the severity of pso‐
riasis, while the Scoring Atopic Dermatitis (SCORAD) and Eczema 
Area and Severity Index (EASI) are instruments for measuring the 
severity of atopic dermatitis. More importantly, in addition to a nu‐
meric score, patients can be stratified into different categories of 
severity. For instance, a PASI score of more than 10 has been con‐
sidered to be moderate–severe psoriasis, although this stratification 
is still debated (Llamas‐Velasco et al., 2017; Schmitt & Wozel, 2005). 
For the EASI, a score of 23 or more was recently suggested to be 
the cut‐off for moderate–severe eczema (Chopra et al., 2017). The 
determination of the affected body surface area (BSA) is an impor‐
tant part in the assessment of vitiligo severity. For this purpose, we 
recently validated the Vitiligo Extent Score (VES) to measure the af‐
fected BSA from the physician's point of view (van Geel et al., 2016). 
The International Initiative for Outcomes (INFO) for vitiligo recom‐
mended the use of the VES for clinical trials (Eleftheriadou et al., 
2018). The VES instrument yields a numeric score, for which the 
interpretability (stratification) is a significant aspect in the develop‐
ment of novel instruments. The relevance of interpretability was 
highlighted by Schmitt et al. in the Harmonizing Outcome Measures 
for Eczema (HOME) roadmap for the development and implementa‐
tion of core outcome sets (COS), currently recognized as a standard‐
ized methodology to develop COSs in dermatology (Schmitt et al., 
2015). Furthermore, this is also acknowledged in the quality criteria 
proposed by the COnsensus‐based Standards for the selection of 
health Measurement INstruments (). Interpretation and stratifica‐
tion of scores obtained by physician‐reported outcome measures 
are usually based on an “anchor question.” The latter is dependent 
on the domain of interest and is generally based on Physician Global 
Assessment (PGA) scores, including a 5‐point scale that is preferably 
validated in advance. For vitiligo, such validated PGA is lacking so 
far. A PGA score may also be useful for standardizing definitions of 
inclusion criteria for clinical trials, epidemiological profiling of popu‐
lations or define global disease evolution over time.
The first aim of this study was to assess the interrater reliability 
and validity of a PGA score for disease extent in an international 
panel of vitiligo experts. The second aim was to determine the me‐
dian BSA values per category for limited, moderate, extensive and 
very extensive vitiligo.
This study was based on a workshop conducted at the San 
Gallicano Institute in Rome during the Vitiligo Global Issues 
Consensus Conference Workshop “Outcome measurement instru‐
ments,” organized from 30 November to 1 December 2016. The 
meeting including the workshop was announced at the local eth‐
ics committees in Rome (M Picardo) as well as in Ghent (reference 
number Ghent: B670201421409). Written informed consent was 
obtained from all patients for the use of their pictures during the 
workshop. Patients were selected randomly (Research Randomizer) 
from a pool of consecutively included patients (prior divided in dif‐
ferent degrees of extent) recruited at the Ghent University Hospital 
(Ghent, Belgium).
The workshop was based on questions and a series of 219 
photographs [mainly with UV pictures (97.2%)] of 20 patients with 
non‐segmental vitiligo including different degrees of extent. Skin 
phototypes were II (2/20), III (13/20), IV (1/20) and V (1/20). As seg‐
mental vitiligo is known to present in a different distribution pattern, 
this subtype was excluded for selection.
All participating physicians were considered vitiligo experts. 
Photographs were presented during the workshop in a randomized 
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different continents rated photographs of non‐segmental vitiligo patients with vary‐
ing degrees of extent with the PGA score. Good interrater agreements (intraclass cor‐
relation coefficient >0.6) were observed between the raters overall and within each 
continent. All hypotheses to evaluate construct validity were confirmed. Median VES 
values per category were for limited 1.10 [IQR: 0.21–1.67], moderate 3.17 [IQR: 1.75–
6.21], extensive 9.58 [IQR: 6.21–13.03] and very extensive 42.67 [IQR: 21.20–42.67]. 
Defined categories for vitiligo extent can be valuable for inclusion criteria and may 
impact future reimbursement criteria.
K E Y W O R D S
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Significance
In this study, we validated a Physician Global Assessment 
(PGA) for extent in vitiligo based on an international work‐
shop including worldwide vitiligo experts. This PGA can be 
used to stratify and interpret the numeric scores obtained 
by other instruments (e.g., Vitiligo Extent Score). The strat‐
ification of patients according to extent scores is crucial to 
define inclusion criteria and may impact future reimburse‐
ment criteria.
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order, and the physicians were asked to score the grade of extent on 
the 5‐point global assessment scale for each patient. This 5‐point 
scale was defined in advance by several investigators (NvG, AW, MB, 
RS) and a methodologist (CP). The PGA was given to the participants 
with a small introduction in advance. To gather more information re‐
garding median values per category for vitiligo extent, the total af‐
fected BSA of each patient was assessed by one expert (NvG) based 
on the pictures through VES.
The COSMIN checklist was used as a guidance for designing and 
reporting our study (Mokkink et al., 2010b, 2010a). The reliability 
of the PGA was evaluated by assessing the interrater agreement 
among all participants. The interrater agreement was calculated 
and interpreted from the following definitions: below 0.4 was con‐
sidered poor, 0.4–0.59 was considered fair, 0.6–0.74 was consid‐
ered good, and higher than 0.74 was defined as excellent (Cicchetti, 
1994). The assessment of validity was based on testing hypotheses 
(construct validity) (Terwee et al., 2007). We tested against four hy‐
potheses (Appendix S1), formulated by two investigators (AW and 
MB) and checked by a methodologist (CP). If 75% of the hypotheses 
were in accordance with the results, it was assumed that there is 
evidence for accepting the construct validity of the PGA (Terwee 
et al., 2007). Three comparison assessment instruments were in‐
cluded in the hypotheses: (a) VES (assessed by 1 vitiligo expert), (b) 
SA‐VES (assessed by the patient for their individual situation), (c) 
BSA 1% rule (assessed by 1 vitiligo expert). The fourth hypothesis 
included an expected difference between limited and extensive vit‐
iligo (Appendix S1).
To gather more information regarding possible categories for 
extent (BSA based on expert VES), the PGA scores of all raters per 
patient were used as anchor question.
Statistical analyses were performed using SPSS 25.0 (SPSS 
Science). The interrater agreement was calculated by intraclass 
correlation coefficient (ICC) and reported as single measures. To 
evaluate the construct validity, four hypotheses were formulated 
including correlations to other extent measures. To test the hypoth‐
eses, Pearson's correlation coefficients were calculated between 
PGA scores and VES, SA‐VES and BSA 1% rule. Missing values were 
excluded from the final analysis. Outliers were investigated; 1 rater 
was excluded based on a negative correlation in scoring answers 
compared to the remaining raters (r = −0.38). In all cases, significance 
level was set at p < 0.05.
A total of 29 vitiligo experts from five continents participated 
in the workshop. Table 1 lists the number of participating physi‐
cians per continent: twenty‐eight scoring sheets were suitable for 
analyses. A good interrater agreement (> 0.6) was observed within 
each separate continent that did not differ significantly (Table 1). 
The highest agreement was achieved for raters from North and 
South America (0.817; 95% CI: 0.694–0.911 and 0.720; 95% CI: 
0.424–0.878, respectively). The overall agreement among all raters 
was 0.671 (95% CI: 0.530–0.816), which is deemed acceptable. All 
hypotheses formulated for validity testing were confirmed, and a 
high correlation was found with VES (Pearson r = 0.932, p < 0.001), 
SA‐VES (r = 0.877, p < 0.001) and BSA 1% rule (r = 0.932, p < 0.001).
Table 2 shows the median and range of VESs per extent cate‐
gory. Median VES values per category were for limited 1.10 [IQR: 
0.21–1.67], moderate 3.17 [IQR: 1.75–6.21], extensive 9.58 [IQR: 
6.21–13.03] and very extensive 42.67 [IQR: 21.20–42.67]. Figure 1 
includes a box plot representing four categories of extent.
Based on the low sample size, exact cut‐off points per category 
could not be defined in this study.
In this study, we validated a PGA for extent assessment in vitil‐
igo using a simple scoring system based on a single question rang‐
ing from no involvement to very extensive. The PGA is an intuitive 
and simple measure that is often used in clinical trials, also known 
as the Investigator Global Assessment (IGA). The stratification of 
patients according to extent scores is crucial to perform research 
on homogenous study populations but can also be a useful tool in 
future reimbursement criteria. Psoriasis is categorized into mild, 
moderate and extensive, and this categorization is widely used 
both as a selection criterion for clinical trials and reimbursement 
of expensive drugs such as biologicals. Importantly, severity in 
vitiligo is more than disease extent only. Yet, a PGA of disease 
extent would be a simple and objective tool to categorize vitiligo 
patients facilitating the interpretation of clinical trials. The avail‐
ability of such an important instrument to better define severity 
is pragmatic. However, this instrument often lacks validity studies 
(Schmitt, Langan, Williams, & Network, 2007). In this pilot proj‐
ect, it was evident that the tool was easy to use and required no 
or minimal training in an international setting. Here, we confirm 
the acceptable interrater reliability based on international vitiligo 
experts from five continents. Satisfactory interrater agreements 
were observed, especially in North America. Furthermore, the 
TA B L E  1   Geographic origins of vitiligo experts present and 
intraclass correlation coefficients
Continent Vitiligo experts (n) ICC; 95% CI
Europe 7 0.647; 0.451–0.816
Asia 9 0.630; 0.464–0.796
Africa 4 0.658; 0.462–0.824
North America 6 0.817; 0.694–0.911
South America 2 0.720; 0.424–0.878
Overall 28 0.671; 0.530–0.816
TA B L E  2   PGA categories based on median VESs
PGA categoriesa Median VES (%) IQR
95% CI for 
the median
Limited extent 1.10 0.21–1.67 1.07–1.10
Moderate extent 3.17 1.75–6.21 2.69–3.55
Extensive 9.58 6.21–13.03 7.72–11.44
Very extensive 42.67 21.20–42.67 30.02–42.67
Notes: CI, confidence interval; IQR, interquartile range; PGA, Physician 
Global Assessment; VES, Vitiligo Extent Score.
aAssessed by all raters. 
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PGA significantly and positively correlated with the VES. Using a 
PGA‐anchor question, the median values of the VES per category 
could be assessed. In comparison, a BSA score of more than 10% 
is considered as moderate psoriasis—here, a median VES of 3.17 
was already considered as moderate extent. Unfortunately, exact 
cut‐off VESs for each extent category could not be assessed in this 
study due to the low sample size. Moreover, based on practical 
limitations, a second scoring round to assess the intra‐rater agree‐
ment was not performed. For these aspects, further research will 
be required. Similarly, an additional study, assessing more patients 
of skin types V and VI will be of interest. However, as the focus 
of this study was extent (surface area affected) and not severity 
(taken into account possible additional aspects to vitiligo extent 
as for instance skin type, location of lesions and disease activ‐
ity), and UV pictures were used in most of the cases, we believe 
any possible bias due to skin phototype is mainly applicable for a 
PGA based on severity. One important critical note related to this 
study is that all participating physicians were experienced vitiligo 
experts from different continents, which can be considered as a 
possible advantage for the stratification into categories, but con‐
sequently may have contributed to the relatively high reliability 
reported in this study. Therefore, it could be valuable to repeat 
this evaluation within a group including dermatologists considered 
as non‐expert in vitiligo. Another point of attention in this study 
was that the number of vitiligo experts of South America was low 
(n = 2); however, as the ICC was within the range of all the other 
continents, this was considered to be useable. Furthermore, only 
extent was assessed here, whereas assessment of severity may 
contribute to a greater interrater variability. However, severity as‐
sessment requires the dimension of the patient's point of view as 
well. Insight into patients’ experiences is crucial to properly define 
severity in a way that is both useful to the physician and reflective 
of the patient's status. For instance, location of lesions or disease 
activity is often not included in a PGA as a separate aspect but 
may significantly impact the patient's experience—especially for 
a skin disease like vitiligo. This brings up a limitation of a tool only 
focusing on extent. Therefore, a thorough investigation within the 
(international) vitiligo patient population may offer additional cri‐
teria to better define vitiligo severity. Also, the lack of validation in 
a clinical trial intervention is an item that will have to be addressed 
in the future.
In conclusion, this study demonstrated the possible categori‐
zation of extent in vitiligo, with good corresponding results among 
physicians worldwide. We also provide a first guide for the inter‐
pretation of the numerical output of the VES based on a physician 
global assessment. The relatively low median BSA value for moder‐
ate extent indicates that clinical decisions will be already impacted 
in the initial categories of body area involvement. Future studies are 
necessary to confirm our findings.
ACKNOWLEDG EMENT
We thank all participants of the VGICC workshop, with a very spe‐
cial word of gratitude to our dear friend Tag Anbar (in memoriam). 
We would like to express our gratitude to the volunteering patients 
for the use of their pictures during the workshop. We acknowledge 
the Vitiligo International Symposium (VIS) and the Vitiligo Global 
Issues Consensus Conference (VIGCC) groups as a supporting or‐
ganizing source of the workshop. Funding sources related to the 
workshop and/or analyses afterwards: EADV grant (EADV Project 
proposal reference number 2015‐030) and LEO Foundation grant 
(Leo Foundation project reference number LF16092). The research 
activities of N. van Geel are supported by the Scientific Research 
Foundation‐Flanders (FWO Senior Clinical Investigator: 1831512N). 
F I G U R E  1   Box plot representing four 
categories of extent. Cases were rated 
based on photographs by the raters using 
a Physician Global Assessment score for 
extent (x‐axis 1: limited; 2: moderate; 3: 
extensive; and 4: very extensive). The 
VES of all cases was assessed by a vitiligo 
expert. Bars represent median ± lower and 
upper limit. Number of raters’ PGA scores 
per category: limited 197; moderate 212; 











1 2 3 4











732  |     VAN GEEL Et AL.
We would like to thank I. Sperduti for local (Italy) statistical support 
and T. Mostien for assistance in processing of data.
CONFLIC T OF INTERE S T
Nanja van Geel : consultant and/or investigator in Pfizer, Laboratoire 
Génévrier, Incyte. Drs van Geel, Speeckaert, Wolkerstorfer, 
Bekkenk, Lommerts and Prinsen were involved to a certain extent in 
the preparative stage of the PGA score used. Albert Wolkerstorfer 
was consultant in Incyte, is investigator in Novartis, and received a 
research grant from AvitaMedical. Iltefat Hamzavi was a consultant 
in Incyte and received fees; an investigator in Bayer (grant paid to 
institution); an investigator in Johnson and Johnson (provided equip‐
ment to institution); an investigator in Incyte, Estee Lauder, Unigen 
Inc, Allergan and Ferndale Laboratories (grant paid to institution); a 
consultant in Pfizer and received fees; and co‐chair in Global Vitiligo 
Foundation and played a non‐compensated role. Amit G. Pandya was 
a consultant in Sun pharmaceuticals and TWi pharmaceuticals; an 
investigator for Aclaris pharmaceuticals, Incyte pharmaceuticals and 
Pfizer pharmaceuticals; and was the board of directors and owned 
stock options with Clarify Medical.
E THIC S
The meeting including the workshop was announced at the local 
ethics committees San Gallicano Institute, Rome (M Picardo), as well 
as approved in Ghent (reference number Ghent: B670201421409).
DATA AVAIL ABILIT Y S TATEMENT
The study design, material and methods (including the PGA score) 
and methodology that support the findings of this study are avail‐
able on request from the corresponding author. The database is not 
available due to privacy and ethical restrictions.
ORCID
Nanja van Geel  https://orcid.org/0000‐0002‐3249‐8195 
Hee Young Kang  https://orcid.org/0000‐0001‐8697‐4292 
Alain Taieb  https://orcid.org/0000‐0002‐0928‐8608 
Reinhart Speeckaert  https://orcid.org/0000‐0002‐9421‐3546 
R E FE R E N C E S
Chopra, R., Vakharia, P. P., Sacotte, R., Patel, N., Immaneni, S., White, 
T., … Silverberg, J. I. (2017). Severity strata for Eczema Area and 
Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis 
(SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and 
body surface area in adolescents and adults with atopic dermatitis. 
British Journal of Dermatology, 177(5), 1316–1321.
Cicchetti, D. V. (1994). Guidelines, criteria, and rules of thumb for 
evaluating normed and standardized assessment instruments in 
psychology. Psychological Assessment, 6(4), 284–890. https ://doi.
org/10.1037/1040‐3590.6.4.284
Consensus‐based Standards for the selection of health Measurement 
Instruments (COSMIN). (n.d.). Retrieved from http://www.cosmin.
nl/index.php (Accessed March 13, 2018).
Eleftheriadou, V., Hamzavi, I., Pandya, A. G., Grimes, P., Harris, J. E., 
Huggins, R. H., … Ezzedine, K. (2018). International Initiative for 
Outcomes (INFO) for vitiligo: Workshops with patients with vitiligo 
on repigmentation. British Journal of Dermatology, 180(3), 574–579.
Llamas‐Velasco, M., de la Cueva, P., Notario, J., Martínez‐Pilar, L., 
Martorell, A., & Moreno‐Ramírez, D. (2017). Moderate psoriasis: 
a proposed definition. Actas Dermo‐Sifiliográficas (English Edition), 
108(10), 911–917. https ://doi.org/10.1016/j.adengl.2017.10.003
Mokkink, L. B., Terwee, C. B., Patrick, D. L., Alonso, J., Stratford, P. W., 
Knol, D. L., … de Vet, H. C. W. (2010a). The COSMIN checklist for 
assessing the methodological quality of studies on measurement 
properties of health status measurement instruments: An interna‐
tional Delphi study. Quality of Life Research, 19(4), 539–549. https ://
doi.org/10.1007/s11136‐010‐9606‐8
Mokkink, L. B., Terwee, C. B., Patrick, D. L., Alonso, J., Stratford, P. W., 
Knol, D. L., … de Vet, H. C. W. (2010b). The COSMIN study reached 
international consensus on taxonomy, terminology, and definitions 
of measurement properties for health‐related patient‐reported out‐
comes. Journal of Clinical Epidemiology, 63(7), 737–745. https ://doi.
org/10.1016/j.jclin epi.2010.02.006
Schmitt, J., Apfelbacher, C., Spuls, P. I., Thomas, K. S., Simpson, E. L., 
Furue, M., … Williams, H. C. (2015). The Harmonizing Outcome 
Measures for Eczema (HOME) roadmap: a methodological frame‐
work to develop core sets of outcome measurements in dermatol‐
ogy. Journal of Investigative Dermatology, 135(1), 24–30. https ://doi.
org/10.1038/jid.2014.320
Schmitt, J., Langan, S., Williams, H. C., & Network, E.‐E. (2007). What are 
the best outcome measurements for atopic eczema? A systematic 
review. Journal of Allergy and Clinical Immunology, 120(6), 1389–1398. 
https ://doi.org/10.1016/j.jaci.2007.08.011
Schmitt, J., & Wozel, G. (2005). The psoriasis area and severity index is the 
adequate criterion to define severity in chronic plaque‐type psoriasis. 
Dermatology, 210(3), 194–199. https ://doi.org/10.1159/00008 3509
Terwee, C. B., Bot, S. D. M., de Boer, M. R., van der Windt, D. A. W. 
M., Knol, D. L., Dekker, J., … de Vet, H. C. W. (2007). Quality criteria 
were proposed for measurement properties of health status ques‐
tionnaires. Journal of Clinical Epidemiology, 60(1), 34–42. https ://doi.
org/10.1016/j.jclin epi.2006.03.012
van Geel, N., Lommerts, J., Bekkenk, M., Wolkerstorfer, A., Prinsen, C. 
A. C., Eleftheriadou, V., … Speeckaert, R. (2016). Development and 
Validation of the Vitiligo Extent Score (VES): an international collabo‐
rative initiative. Journal of Investigative Dermatology, 136(5), 978–984. 
https ://doi.org/10.1016/j.jid.2015.12.040
SUPPORTING INFORMATION
Additional supporting information may be found online in the 
Supporting Information section at the end of the article. 
How to cite this article: van Geel N, Wolkerstorfer A, Ezzedine 
K, et al; On behalf of all the participants of the Rome 
International VGICC /VIS Workshop. Validation of a physician 
global assessment tool for vitiligo extent: Results of an 
international vitiligo expert meeting. Pigment Cell Melanoma 
Res. 2019;32:728–733. https ://doi.org/10.1111/pcmr.12784 
     |  733VAN GEEL Et AL.
APPENDIX 1
Participants of the VGICC to the workshop
Tag Anbar (Egypt)†, Mohamed Anbar (Egypt), Laïla Benzekri 
(Morocco), Marcel Bekkenk (Netherlands), Markus Böhm (Germany), 
Caïo Castro (Brasil), Tania Cestari (Brasil), Samia Esmat (Egypt), 
Viktoria Eleftheriadou (United Kingdom), Khaled Ezzedine (France), 
Yvon Gauthier (France), Maria Gnarra (Italy), Iltefat Hamzavi (USA), 
John E. Harris (USA), Jorge Hinojosa (USA), Min Bae Jung (S Korea), 
Hee Young Kang (S Korea), Ichiro Katayama (Japan), Ki‐Ho Kim 
(S Korea), Prasad Kumarasinghe (Australia), Cheng‐Che Eric Lan 
(Taiwan), Seung‐Chung Lee (S Korea), Caroline Le Poole (USA), Henry 
Lim (USA), Silvia Moretti (Italy), Amit Pandya (USA), Mauro Picardo 
(Italy), Davinder Parsad (India), Noufal Raboobee (South Africa), 
Julien Seneschal (France), Reinhart Speeckaert (Belgium), Richard 
Spritz (USA), Tamio Suzuki (Japan), Alain Taieb (France), Nanja van 
Geel (Belgium), Albert Wolkerstorfer (Netherlands) and Flora Xiang 
(Rep China).
